AHA today voiced support for a number of proposed changes to the Medicare Advantage and Part D programs aimed at increasing plan negotiating power to lower drug prices, but emphasized “the importance of strong patient protections to ensure continuity of care, the application of medical necessity, an expedited appeals process, and required review and approval of MA step therapy plans by respective Pharmacy and Therapeutic Committees.” The proposed rule would allow Part D plans to exclude certain drugs from their formularies with the objective of negotiating lower drug prices; codify a recent change in policy that allowed MA plans to require beneficiaries to try cost-effective Part B drug therapies before progressing to more expensive options; require Part D plans to implement by 2020 electronic tools to inform prescribers of beneficiary-specific drug coverage and lower-cost therapeutic alternatives available to the enrollee; and require Part D plans to include information about changes in drug prices and lower-cost therapeutic alternatives in their explanation of benefits.

Related News Articles

Insights and Analysis
AHA board member Becky Hultberg hopes to help the AHA create solutions for rural hospitals, among other initiatives.
Headline
The House Energy and Commerce Committee today held a hearing on its discussion draft of bipartisan legislation to address surprise medical bills.
Headline
The House Ways and Means Committee today held a hearing on “Pathways to Universal Health Coverage,” which debated various options to expand access to health…
Insights and Analysis
AHA board member Delvecchio Finley leads Alameda (Calif.) Health System in bringing more services to the community it serves, meeting patients where they are…
Headline
The Centers for Medicare…
Headline
The AHA today voiced support for legislation to revise and extend federal programs to develop the nursing workforce.